相关实验视频

Updated: Jul 16, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在癌症治疗中将PD-1/PD-L1阻塞与I型干扰素结合起来

Ali Razaghi¹, Mickaël Durand-Dubief², Nele Brusselaers^3,4,5

¹Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Frontiers in immunology

|September 11, 2023

概括

将I型干扰素 (IFN) 与PD-1/PD-L1阻断相结合,通过增加瘤内的T细胞活性来增强癌症免疫力. 这种免疫疗法组合有望改善各种癌症患者的存活率.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症治疗癌症治疗

背景情况:

编程细胞死亡蛋白1 (PD-1) 和它的连接体 (PD-L1) 是免疫检查点蛋白,瘤利用它们来逃避免疫监测.
阻止PD-1/PD-L1相互作用可以释放T细胞介导的抗瘤免疫力.
I型干扰素 (IFN) 是调节免疫反应的细胞因子,可以增强抗瘤活性.

研究的目的:

评估将PD-1/PD-L1阻断与I型干扰素治疗结合用于癌症治疗的协同效应.
评估这种组合对抗瘤免疫反应和临床结果的影响.

主要方法:

关于I型IFN和PD-1/PD-L1阻塞组合的临床前和临床数据的审查.
在瘤中分析免疫细胞透,激活和记忆T细胞生成.
在早期临床试验 (I期和II期) 中评估安全性,疗效和患者反应.

主要成果:

组合疗法显著增加了瘤内的T细胞透和激活.
协同作用增强瘤细胞对PD-1/PD-L1阻断的敏感性,并促进记忆T细胞的产生.
I/II期试验表明,在各种癌症类型,特别是黑色素瘤中,可接受的安全性和有希望的疗效.

结论:

将I型IFN与PD-1/PD-L1阻断相结合,是增强抗瘤免疫力和改善患者存活率的有希望的策略.
需要进一步进行III/IV期试验,将这种组合与标准治疗进行比较,并评估长期结果和副作用.
识别预测生物标志物对于优化患者选择和监测治疗反应至关重要.

关键词:

在PD-1中使用PD-1.在PD-L1中.癌症癌症癌症癌症癌症免疫疗法免疫疗法干扰子干扰子干扰子干扰素一个 (IFNa)

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...